Prediction of Therapeutic Response of Apatinib in Recurrent Gliomas

Sponsor
The First Affiliated Hospital of Zhengzhou University
Study ID
NCT04216550
Status
Unknown

Conditions

  • Recurrent Glioma

Eligibility Criteria

Sex
ALL
Age
18 Years - 90 Years
Healthy Volunteers
Not accepted

Interventions

  • Apatinib — DRUG
    Apatinib 0.5g orally daily until the untolerable toxicities, disease progression or death

Study Details

Apatinib, also known as YN968D1, is a small-molecule tyrosine kinase inhibitor (TKI) that selectively binds to and inhibits vascular endothelial growth factor receptor 2 (VEGFR-2). This study aims to collect clinical, radiological and histopathology imaging including detailed radiological data, survival data, clinical parameters, molecular pathology and images of HE slices in patients with recurrent gliomas whose are treated with Apatinib, for evaluating the efficacy and safety of Apatinib. Moreover, by leveraging artificial intelligence, this study seeks to construct and refine MR and histopathology imaging based algorithms that are able to predict the responses to Apatinib of patients with recurrent gliomas.

Key Dates

Start date
Jan 1, 2018
Status verified
Feb 2021
Primary completion
Jan 1, 2025
Completion
Jun 1, 2025

Study Design

Enrollment
600 participants (estimated)

Arms

  • Arm: Apatinib
    Apatinib 0.5g orally daily until the untolerable toxicities, disease progression or death

Primary Outcome Measure

Changes of Response to Treatment [ Time Frame: From enrollment to progression of disease. Estimated about 6 months ]

Central Contacts

Related Studies